Metastatic gastrointestinal stromal tumor (GIST) is a high-grade malignancy with a poor prognosis. In recent years, the relationship between GISTs and activation of the cell surface transmembrane receptor KIT has been well established. Imatinib mesylate inhibits the KIT signal transduction pathway, yielding a good response in half of patients with metastatic or unresectable GISTs. We report a patient with GIST hepatic metastases treated with imatinib mesylate. Cystic changes in the metastatic tumors were found on both computed tomography (CT) and sonography. While both CT scan and sonography showed changes in response to treatment, sonography demonstrated some features that CT did not, such as the change in wall thickness, mural nodules, and fluid-fluid levels. However, CT scan after contrast showed tumor viability and provided an overview of the lesions that sonography did not. We discuss the sonographic features of GISTs treated with imatinib mesylate and compare the findings with CT scan.